Table 3 Most common (>20%) non-serious adverse events
From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Adverse event | Number of patients and percentage |
|---|---|
Stomatitis | 12, 80% |
Proteinuria | 11, 73.3% |
White blood cell count decrease | 8, 53.3% |
Hyperglycaemia | 7, 46.7% |
Pyrexia | 6, 40% |
Gamma-glutamyltransferase increased | 6, 40% |
Anemia | 5, 33.3% |
Platelet count decrease | 5, 33.3% |
Hypoalbuminaemia | 5, 33.3% |
Blood cholesterol increased | 5, 33.3% |
Fatigue | 4, 26.7% |
Blood alkaline phosphatase increased | 4, 26.7% |
ALT increase | 3, 20% |
Interstitial lung disease | 3, 20% |